Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nissen fills Topol’s shoes

Executive Summary

Medical Director of the Cleveland Clinic's Cardiovascular Coordinating Center Steven Nissen is named interim chairman of the hospital's Department of Cardiovascular Medicine, effective immediately. Nissen replaces Eric Topol, who recently resigned (1"The Pink Sheet" Feb. 13, 2006, In Brief). A search committee will soon begin interviewing and considering external and internal candidates - including Nissen - to permanently fill the position. Nissen, who joined the Cleveland Clinic in 1992, has served as vice-chairman of the cardiology department, section head of clinical cardiology and director of the coronary intensive care unit...

You may also be interested in...

Topol departs Cleveland Clinic

Eric Topol, an outspoken critic of COX-2 inhibitors and a witness in Vioxx product liability cases, resigns from his position as chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic. Topol will join the Department of Genetics at Case Western University. He will continue to work with the Cleveland Clinic as a consultant and serve as program director of an NIH grant in collaboration with the clinic. A study of Pfizer's COX-2 Celebrex will be conducted at the Cleveland Clinic under the direction of Steven Nissen (1"The Pink Sheet" Dec. 19, 2005, p. 18)...

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts